Teva Pharmaceutical Industries Limited Stock News

Teva Pharmaceutical Industries Ltd. (TEVA) witnessed a jump in share price last session on above-average trading volume.

These all handily outperformed the market last year and could do the same in 2023.

Sometimes, business models that sound safe still fail to deliver for shareholders.

Sometimes, business models that sound safe still fail to deliver for shareholders.

Shares look to have been undergoing a bottoming pattern for well over three years now. Although near-term EPS revisions have been faltering, Teva's relationship between its valuation and profitability

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.

This mix of growth and value stocks can outperform in a challenging environment.

This mix of growth and value stocks can outperform in a challenging environment.

'Tis the season for 2023 stock picks, and UBS analysts are out with their favorites, including AMD, Target, and Nike

This biotech stock just jumped over 180% in a single day, and investors want to know if there could be more big gains ahead.

The FDA grants priority review to Emergent's regulatory filing seeking approval for an OTC version of its Narcan nasal spray. A final decision is expected by March 2023-end.

These three leading companies are ripe for the picking and may never be this cheap again.

These three leading companies are ripe for the picking and may never be this cheap again.

Teva Pharmaceutical Indus (NYSE:TEVA) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 0 1 2 0

Analysts have provided the following ratings for Teva Pharmaceutical Indus (NYSE:TEVA) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 0